3 December 2008 - Tibotec Pharmaceuticals, announced today that the European Commission adopted the decision to broaden the indication for PREZISTA (darunavir), a protease inhibitor, in combination with ritonavir and other antiretroviral medicinal products to the treatment of HIV-1 infection in all treatment-experienced adult patients.
The details can be read here.
No comments:
Post a Comment